INOVIO Pharmaceuticals, a Plymouth Meeting, Pennsylvania-based biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, has priced an underwritten public offering expected to raise about $75 million, the company announced on November 5, 2026.
Inside the Offering
INOVIO is selling 58,747,235 shares of common stock at $1.05 per share. Some investors will instead receive pre-funded warrants to buy 12,681,337 shares at $1.049 each. A pre-funded warrant is paid for almost entirely upfront and can be converted into a share for a small additional payment.
Underwriters also have a 30-day option to buy up to 10,714,285 additional shares. The roughly $75 million in gross proceeds is before underwriting discounts, commissions, and other expenses, and doesn’t include that option. The offering was expected to close on or about November 9, 2026.
Jefferies and Piper Sandler are serving as joint book-running managers, with H.C. Wainwright & Co. as lead manager.
About INOVIO
INOVIO’s technology optimizes the design and delivery of DNA medicines, which the company says teach the body to manufacture its own disease-fighting tools.
Forward-Looking Statements
This release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO’s securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in INOVIO’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Source: INOVIO Pharmaceuticals, https://ir.inovio.com/news/news-details/2026/INOVIO-Announces-Pricing-of-Approximately-75-Million-Public-Offering/default.aspx on November 5, 2026. Republished with credit to the original author. Read the original article.
